Aliskiren
( DrugBank: Aliskiren / KEGG DRUG: Aliskiren, Aliskiren fumarate )
4 diseases
| ID | Disease name (Link within this page) | Number of trials |
|---|---|---|
| 66 | IgA nephropathy | 4 |
| 167 | Marfan syndrome | 1 |
| ID | Disease name (Link within this page) | Number of trials |
|---|---|---|
| 222 | Primary nephrotic syndrome | 2 |
| 223 | Primary membranoproliferative glomerulonephritis | 4 |
66. IgA nephropathy
Clinical trials : 407 / Drugs : 342 - (DrugBank : 73) / Drug target genes : 40 - Drug target pathways : 146
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|
167. Marfan syndrome
Clinical trials : 26 / Drugs : 50 - (DrugBank : 11) / Drug target genes : 10 - Drug target pathways : 52
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|
222. Primary nephrotic syndrome
Clinical trials : 576 / Drugs : 519 - (DrugBank : 130) / Drug target genes : 108 - Drug target pathways : 219
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|
223. Primary membranoproliferative glomerulonephritis
Clinical trials : 243 / Drugs : 296 - (DrugBank : 84) / Drug target genes : 46 - Drug target pathways : 169
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|